BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 964 filers reported holding BAXTER INTL INC in Q2 2017. The put-call ratio across all filers is 0.35 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2023 | $338,662 | -4.3% | 8,760 | -6.6% | 0.01% | -12.5% |
Q3 2023 | $354,001 | -17.0% | 9,380 | +0.2% | 0.02% | -15.8% |
Q2 2023 | $426,578 | +2.6% | 9,363 | -8.7% | 0.02% | 0.0% |
Q1 2023 | $415,862 | -9.5% | 10,253 | +13.8% | 0.02% | -5.0% |
Q4 2022 | $459,291 | -5.3% | 9,011 | 0.0% | 0.02% | -16.7% |
Q3 2022 | $485,000 | -12.6% | 9,011 | +4.3% | 0.02% | -11.1% |
Q2 2022 | $555,000 | -17.4% | 8,636 | -0.3% | 0.03% | -3.6% |
Q1 2022 | $672,000 | -9.3% | 8,666 | +0.4% | 0.03% | -3.4% |
Q4 2021 | $741,000 | +7.1% | 8,635 | +0.3% | 0.03% | 0.0% |
Q3 2021 | $692,000 | -0.6% | 8,605 | -0.5% | 0.03% | 0.0% |
Q2 2021 | $696,000 | -5.7% | 8,647 | -1.1% | 0.03% | -9.4% |
Q1 2021 | $738,000 | -4.5% | 8,747 | -9.2% | 0.03% | -11.1% |
Q4 2020 | $773,000 | +22.3% | 9,638 | +22.7% | 0.04% | +9.1% |
Q3 2020 | $632,000 | -6.5% | 7,857 | 0.0% | 0.03% | -13.2% |
Q2 2020 | $676,000 | +6.0% | 7,857 | 0.0% | 0.04% | -5.0% |
Q1 2020 | $638,000 | -2.9% | 7,857 | 0.0% | 0.04% | +21.2% |
Q4 2019 | $657,000 | -4.8% | 7,857 | -0.3% | 0.03% | -13.2% |
Q3 2019 | $690,000 | -7.3% | 7,883 | -13.2% | 0.04% | -5.0% |
Q2 2019 | $744,000 | -3.1% | 9,082 | -3.8% | 0.04% | -7.0% |
Q1 2019 | $768,000 | +17.4% | 9,440 | -5.0% | 0.04% | +7.5% |
Q4 2018 | $654,000 | -14.8% | 9,940 | -0.2% | 0.04% | -4.8% |
Q3 2018 | $768,000 | -3.6% | 9,957 | -7.8% | 0.04% | -8.7% |
Q2 2018 | $797,000 | +8.4% | 10,796 | -4.4% | 0.05% | +7.0% |
Q1 2018 | $735,000 | +2.8% | 11,297 | +2.1% | 0.04% | +7.5% |
Q4 2017 | $715,000 | +3.9% | 11,069 | +0.9% | 0.04% | +2.6% |
Q3 2017 | $688,000 | +23.1% | 10,969 | +18.9% | 0.04% | +18.2% |
Q2 2017 | $559,000 | +30.9% | 9,223 | +12.0% | 0.03% | +26.9% |
Q1 2017 | $427,000 | +13.3% | 8,234 | -2.9% | 0.03% | +13.0% |
Q4 2016 | $377,000 | -6.2% | 8,484 | +0.6% | 0.02% | -11.5% |
Q3 2016 | $402,000 | +1.5% | 8,434 | -3.8% | 0.03% | +4.0% |
Q2 2016 | $396,000 | +9.4% | 8,764 | -0.6% | 0.02% | +4.2% |
Q1 2016 | $362,000 | +10.0% | 8,816 | +2.3% | 0.02% | +9.1% |
Q4 2015 | $329,000 | +9.3% | 8,621 | -6.2% | 0.02% | 0.0% |
Q3 2015 | $301,000 | -60.4% | 9,187 | -17.2% | 0.02% | -56.9% |
Q1 2015 | $760,000 | -99.9% | 11,090 | +6.9% | 0.05% | +2.0% |
Q4 2014 | $760,531,000 | +5.8% | 10,377 | +3.6% | 0.05% | -3.8% |
Q3 2014 | $718,561,000 | +21.9% | 10,012 | +25.0% | 0.05% | +23.8% |
Q1 2014 | $589,523,000 | +9.7% | 8,012 | +3.7% | 0.04% | +10.5% |
Q4 2013 | $537,343,000 | +10.3% | 7,726 | +4.2% | 0.04% | +2.7% |
Q3 2013 | $487,157,000 | -5.2% | 7,416 | -0.1% | 0.04% | -11.9% |
Q2 2013 | $513,983,000 | – | 7,420 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
13D Management LLC | 194,807 | $11,794,000 | 4.18% |
Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |